Literature DB >> 23536414

Ulcerogenic and intestinal motility/transit stimulating actions of nevirapine in albino Wistar rats.

Elizabeth Bassey Umoren1, Agona Odeh Obembe, Eme Effiom Osim.   

Abstract

The antiretroviral is a non-nucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1. This study was undertaken to investigate the effect of nevirapine (NVP) administration on gastric acid secretion, pepsin secretion, mucosal secretion, intestinal motility, and transit using apparently healthy albino Wistar rats. Eighty albino Wistar rats (50-125 g body weight) from the start of the experiment were used for the study. Rats in the control group were fed normal rodent chow, while the NVP group was fed by gavage NVP (0.4 mg/kg body weight) two times daily (07:00 and 18:00 hours) in addition to normal rodent chow for 12 weeks. All animals were allowed free access to clean drinking water. Mean basal gastric output and peak acid output following histamine administration in the NVP-treated group were significantly higher (p < 0.001, respectively) compared to the control. Following cimetidine administration, there was significant decrease (p < 0.001) in peak acid output in the NVP-treated group compared to the control. The concentration of gastric pepsin, adherent mucus secretion, and mean value for ulcer score were significantly higher (p < 0.001) compared to their control group, respectively. There were significant increases (p < 0.05, respectively) in intestinal motility and basal contraction (p < 0.05) and increase in intestinal transit of the ileum of NVP-treated rats compared to their control, respectively. Results of the study suggest that NVP administration might provoke gastric ulceration in rats which may be caused by high pepsin, high basal acid output, and increased intestinal motility and transit.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23536414     DOI: 10.1007/s13105-013-0243-x

Source DB:  PubMed          Journal:  J Physiol Biochem        ISSN: 1138-7548            Impact factor:   4.158


  18 in total

1.  Mitochondrial toxicity in HIV-HCV coinfection: It depends on the choice of antiretroviral drugs?

Authors:  Raffaele Bruno; Paolo Sacchi; Gaetano Filice
Journal:  Hepatology       Date:  2002-02       Impact factor: 17.425

2.  HIV/HCV co-infection: clinical and therapeutic challenges.

Authors:  Fabrizio Ensoli; Maria Caterina Sirianni
Journal:  AIDS       Date:  2002-07-05       Impact factor: 4.177

3.  Improved survival among HIV-infected individuals following initiation of antiretroviral therapy.

Authors:  R S Hogg; K V Heath; B Yip; K J Craib; M V O'Shaughnessy; M T Schechter; J S Montaner
Journal:  JAMA       Date:  1998-02-11       Impact factor: 56.272

4.  Association of gastric acid and mucus secretion level with low-dose aspirin-induced gastropathy.

Authors:  Katsunori Iijima; Nobuyuki Ara; Yasuhiko Abe; Tomoyuki Koike; Wataru Iwai; Toshimitsu Iwabuchi; Takafumi Ichikawa; Yayoi Kamata; Kazuhiko Ishihara; Tooru Shimosegawa
Journal:  J Gastroenterol       Date:  2011-10-27       Impact factor: 7.527

5.  Therapeutic drug monitoring of atazanavir: surveillance of pharmacotherapy in the clinic.

Authors:  John E Ray; Debbie Marriott; Mark T Bloch; Andrew J McLachlan
Journal:  Br J Clin Pharmacol       Date:  2005-09       Impact factor: 4.335

6.  Gastric gel mucus thickness: effect of distention, 16,16-dimethyl prostaglandin e2, and carbenoxolone.

Authors:  M Bickel; G L Kauffman
Journal:  Gastroenterology       Date:  1981-04       Impact factor: 22.682

7.  Assay of tracheal pepsin as a marker of reflux aspiration.

Authors:  Usha Krishnan; John D Mitchell; Isabella Messina; Andrew S Day; Timothy D Bohane
Journal:  J Pediatr Gastroenterol Nutr       Date:  2002-09       Impact factor: 2.839

Review 8.  Prostaglandins, NSAIDs, and gastric mucosal protection: why doesn't the stomach digest itself?

Authors:  John L Wallace
Journal:  Physiol Rev       Date:  2008-10       Impact factor: 37.312

9.  Suppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapy.

Authors:  J M Raboud; J S Montaner; B Conway; S Rae; P Reiss; S Vella; D Cooper; J Lange; M Harris; M A Wainberg; P Robinson; M Myers; D Hall
Journal:  AIDS       Date:  1998-09-10       Impact factor: 4.177

Review 10.  Comparative pharmacodynamics and pharmacokinetics of cimetidine and ranitidine.

Authors:  D A Richards
Journal:  J Clin Gastroenterol       Date:  1983       Impact factor: 3.062

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.